Access
To read this story in full you will need to login or make a payment (see right).
News and Views
Nature 443, 153-154 (14 September 2006) | doi:10.1038/443153a; Published online 13 September 2006
Open Innovation Challenges
-
Methods of Modeling Adaptation in Populations
The analysis of adaptation with a population is a frequently encountered computational modeling scen...
-
Direct Molecular Detection of Proteins and Nucleic Acids
This Challenge is looking for novel approaches to protein and nucleic acid detection. This is an Id...
- More Challenges
- Powered by:
nature jobs
Senior Lecturer / Reader
- King's College London
- London United Kingdom
Materials Engineer
- Praj Matrix - Praj Industries Ltd
- Pune, Maharashtra Pune-411021 India
Cancer biology: Can less be more for p53?
Anton Berns1
Abstract
The tumour-suppressor protein p53 is often mutated in cancer. But it seems that p53 deficiency is not all bad, and inhibiting this protein might mitigate toxic side effects of chemotherapy and radiotherapy.
The p53 protein gained its reputation as the 'guardian of the genome' because it mediates the cell's response to certain types of injury, relaying signals from both the DNA-damage response pathway and the oncogenic (tumour-promoting) stress pathway. Defects in these pathways are associated with a predisposition to cancer, and because they converge on p53, it has always been assumed that they act primarily through this crucial protein.
- Anton Berns is in the Division of Molecular Genetics and Centre of Biomedical Genetics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
Email: a.berns@nki.nl
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Identification of IGFBP-6 as an effector of the tumor suppressor activity of SEMA3BOncogene Original Article
